Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) Research & Development (2023 - 2025)

Xenetic Biosciences (XBIO) has disclosed Research & Development for 3 consecutive years, with $756482.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 105.57% year-over-year to $756482.0, compared with a TTM value of $3.3 million through Sep 2025, up 3.5%, and an annual FY2024 reading of $3.3 million, down 5.91% over the prior year.
  • Research & Development was $756482.0 for Q3 2025 at Xenetic Biosciences, up from $656557.0 in the prior quarter.
  • Across five years, Research & Development topped out at $1.0 million in Q4 2024 and bottomed at $367985.0 in Q3 2024.
  • Average Research & Development over 3 years is $797312.8, with a median of $879029.0 recorded in 2025.
  • The sharpest move saw Research & Development tumbled 63.94% in 2024, then surged 105.57% in 2025.
  • Year by year, Research & Development stood at $975628.0 in 2023, then grew by 6.83% to $1.0 million in 2024, then fell by 27.42% to $756482.0 in 2025.
  • Business Quant data shows Research & Development for XBIO at $756482.0 in Q3 2025, $656557.0 in Q2 2025, and $879029.0 in Q1 2025.